{"id":2564,"date":"2025-10-15T14:42:29","date_gmt":"2025-10-15T13:42:29","guid":{"rendered":"https:\/\/lenus-healthcare.com\/?p=2564"},"modified":"2026-06-24T14:52:20","modified_gmt":"2026-06-24T13:52:20","slug":"breast-cancer","status":"publish","type":"post","link":"https:\/\/lenus-healthcare.com\/en\/breast-cancer\/","title":{"rendered":"FDA Approval of Imlunestrant for ER-Positive, HER2-Negative, ESR1-Mutated Breast Cancer"},"content":{"rendered":"

Metastatic breast cancer with estrogen receptor positivity (ER-positive) and HER2 negativity represents one of the most common and challenging subtypes of breast cancer. In many patients, mutations in the ESR1<\/strong> gene result in resistance to endocrine therapies, making long-term disease control difficult.<\/p>\n

On September 25, 2025, the U.S. Food and Drug Administration (FDA) approved Imlunestrant (Inluriyo, Eli Lilly and Company)<\/strong>, an estrogen receptor antagonist, for the treatment of adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer whose disease has progressed following at least one line of endocrine therapy.<\/p>\n

This approval was based on results from the EMBER-3 clinical trial (NCT04975308)<\/strong>, which demonstrated improved efficacy and safety of Imlunestrant compared with standard endocrine therapy options (FDA, 2025).<\/p>\n

As the pharmaceutical<\/a><\/strong> landscape continues to evolve, access to innovative medicines remains essential for improving patient outcomes and supporting healthcare systems worldwide.<\/p>\n

For international supply and commercial inquiries regarding this product, please contact the Lenus Health sales team.<\/strong><\/a><\/p><\/blockquote>\n

Table of Contents<\/strong><\/p>\n

    \n
  1. Introduction to Imlunestrant and Mechanism of Action<\/a><\/li>\n
  2. EMBER-3 Clinical Trial<\/a><\/li>\n
  3. Dosage and Administration<\/a><\/li>\n
  4. Common Adverse Events<\/a><\/li>\n
  5. Role of Guardant360 CDx as Companion Diagnostic<\/a><\/li>\n
  6. FDA Expedited Programs<\/a><\/li>\n
  7. Conclusion and Future Perspectives<\/a><\/li>\n
  8. Frequently Asked Questions (FAQs)<\/a><\/li>\n<\/ol>\n

    1. Introduction to Imlunestrant and Mechanism of Action<\/h2>\n

    Imlunestrant (Inluriyo) is a selective estrogen receptor antagonist that effectively inhibits estrogen receptor signaling pathways. It is particularly beneficial for patients with ESR1 mutations, which are associated with resistance to conventional endocrine therapies (FDA, 2025).<\/p>\n

    FDA Approves Yartemlea: First Approved Treatment for TA-TMA After Stem Cell Transplant<\/a><\/p><\/blockquote>\n